HCG

HCG is FDA-approved for selected cases of hypogonadotropic hypogonadism in males, prepubertal cryptorchidism, and induction of ovulation in infertile women. In non-medical bodybuilding contexts, HCG is commonly referenced for maintaining testicular function during suppressive cycles and supporting recovery after cycle completion, though such use falls outside approved indications.

HCG's extended half-life of approximately 33–39 hours allows for less frequent administration than daily injections. In non-medical contexts, HCG is commonly referenced at 500 IU two to three times weekly for maintenance, or higher doses three times weekly during recovery protocols. Medical dosing is individualized by a clinician based on the indication.

HCG is often referenced as a component of post-cycle therapy rather than requiring PCT itself. After HCG use, some individuals may transition to selective estrogen receptor modulators such as Clomid or Nolvadex to support continued endogenous testosterone recovery through a different mechanism.

HCG acts virtually identically to luteinizing hormone (LH), stimulating the Leydig cells of the testes to produce testosterone and other gonadal steroid hormones. This LH-mimetic activity is the basis for its medical use in hypogonadotropic hypogonadism and its community-referenced applications in cycle support and recovery.

HCG's effects on testosterone production begin after administration, with its extended half-life supporting activity over approximately 33–39 hours. In clinical case reports of anabolic steroid-induced azoospermia, recovery of spermatogenesis was observed over a 3-month treatment period with HCG and hMG.

There is no single compound that is universally best for recovery. HCG directly stimulates testosterone production through LH receptor activation, while selective estrogen receptor modulators like Clomid and Nolvadex work by increasing endogenous gonadotropin release. The appropriate approach depends on individual circumstances and goals.

HCG acts primarily through LH receptor activation, while HMG 150 IU contains both LH and FSH activity. This makes HMG potentially more relevant for fertility-focused protocols that require FSH stimulation in addition to LH-like activity. The two are sometimes referenced in combination.

HCG directly mimics LH at the receptor level, stimulating testosterone production independent of the hypothalamic-pituitary axis. Clomid works indirectly by blocking estrogen feedback at the hypothalamus and pituitary, increasing endogenous gonadotropin release. These different mechanisms are why they are sometimes referenced together in recovery protocols.

The 5000 IU vial strength is a standard pharmaceutical presentation. Doses are typically measured in IU and administered based on the desired concentration after reconstitution. For reference, FDA labeling for hypogonadotropic hypogonadism references regimens of 500–1,000 IU or 4,000 IU per injection depending on the protocol.

HCG by Dragon Pharma is available in 2500 IU and 5000 IU per vial strengths. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

Yes. Published laboratory reports are available for both strengths. The 5000 IU vial was measured at 4768 IU (95.36% of label claim) on September 26, 2023. The 2500 IU vial was measured at 2976 IU (119.04% of label claim) on September 28, 2023. Complete reports can be viewed in the Lab Reports tab.

Lyophilized HCG is typically reconstituted with a suitable diluent such as bacteriostatic water. The volume of diluent added determines the concentration of the resulting solution—for example, adding 2 mL to a 5000 IU vial yields 2500 IU/mL. Proper sterile technique should be used during reconstitution.